Metrics as of 10/13/2026, 06:45 PM (Berlin time), refresh in progress.
Voyager Therapeutics Stock
Voyager Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Alfred W. Sandrock Jr.
- Employees
- 141
- Market cap
- $117 M
- IPO
- 11/11/2015
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The…
Voyager Therapeutics stock: price history
1D
-7.8%
1W
-22.4%
1M
-37.7%
6M
-54.0%
YTD
-51.7%
1Y
-64.4%
2Y
-76.0%
5Y
-53.7%
10Y
-84.6%
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~38% stronger price swings than usual
Ask the agents about Voyager Therapeutics
Analyst assessment of Voyager Therapeutics
PRICE TARGET LOW
US$8.00
CONSENSUS
US$14.40
MEDIAN
US$18.00
PRICE TARGET HIGH
US$18.00
0
STRONG BUY
17
BUY
4
HOLD
0
SELL
0
STRONG SELL
21
TOTAL · Buy
As of: 10/08/2026
Voyager Therapeutics stock metrics
P/E
-1.05
P/B
0.75
EV/EBITDA
-1.1
RETURN ON EQUITY
-15.9%
NET MARGIN
-773.2%
DEBT/EQUITY
0.21
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
83.7%
FLOAT SHARES
51,593,161
AVG. DAILY VOLUME (30D)
677,278
Institutional holders
Comparable stocks
Frequently asked questions about Voyager Therapeutics stock
What does Voyager Therapeutics do?
Voyager Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Alfred W. Sandrock Jr., the company employs around 141 people.
The IPO was on 11/11/2015; the stock trades on NASDAQ under the ticker VYGR.
What do analysts say about Voyager Therapeutics stock?
21 analysts rate the stock, the consensus is Buy (as of 10/08/2026).
The average price target is US$14.40, ranging from US$8.00 to US$18.00, with a median of US$18.00.
This is an external assessment, not a statement by Market Jury.
When does Voyager Therapeutics report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 38% stronger than usual.
Does Voyager Therapeutics pay a dividend?
No, Voyager Therapeutics currently does not pay a dividend.
Which stocks are comparable to Voyager Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Voyager Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Voyager Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.